Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis.
antineoplastic protocols
cytotoxicity, immunologic
hematologic neoplasms
immunity, cellular
immunotherapy
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
accepted:
16
03
2023
medline:
14
4
2023
entrez:
12
4
2023
pubmed:
13
4
2023
Statut:
ppublish
Résumé
Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. Furthermore, differential diagnosis from sepsis, highly incident in these patients, is challenging. Suitable laboratory tools could be determinant for their appropriate management. Sixty-two patients treated with CAR-T cell immunotherapy for hematological malignancies (n=46 with CD19-positive diseases, n=16 with multiple myeloma) were included. Plasma samples were obtained: before CAR-T cell infusion (baseline); after 24-48 hours; at suspicion of any toxicity onset and 24-48 hours after immunomodulatory treatment. Biomarkers of endothelial dysfunction (soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble TNF receptor 1 (sTNFRI), thrombomodulin (TM), soluble suppression of tumorigenesis-2 factor (ST2), angiopoietin-2 (Ang-2)), innate immunity activation (neutrophil extracellular traps (NETs), soluble C5b-9 (sC5b-9)) and hemostasis/fibrinolysis (von Willebrand Factor antigen (VWF:Ag), ADAMTS-13 (A13), α2-antiplasmin (α2-AP), plasminogen activator inhibitor-1 antigen (PAI-1 Ag)) were measured and compared with those in cohorts of patients with sepsis and healthy donors. Patients who developed CAR-T cell toxicities presented increased levels of sVCAM-1, sTNFRI and ST2 at the clinical onset versus postinfusion values. Twenty-four hours after infusion, ST2 levels were good predictors of any CAR-T cell toxicity, and combination of ST2, Ang-2 and NETs differentiated patients requiring intensive care unit admission from those with milder clinical presentations. Association of Ang-2, NETs, sC5b-9, VWF:Ag and PAI-1 Ag showed excellent discrimination between severe CAR-T cell toxicities and sepsis. This study provides relevant contributions to the current knowledge of the CAR-T cell toxicities pathophysiology. Markers of endotheliopathy, innate immunity activation and hemostatic imbalance appear as potential laboratory tools for their prediction, severity and differential diagnosis.
Sections du résumé
BACKGROUND
Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. Furthermore, differential diagnosis from sepsis, highly incident in these patients, is challenging. Suitable laboratory tools could be determinant for their appropriate management.
METHODS
Sixty-two patients treated with CAR-T cell immunotherapy for hematological malignancies (n=46 with CD19-positive diseases, n=16 with multiple myeloma) were included. Plasma samples were obtained: before CAR-T cell infusion (baseline); after 24-48 hours; at suspicion of any toxicity onset and 24-48 hours after immunomodulatory treatment. Biomarkers of endothelial dysfunction (soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble TNF receptor 1 (sTNFRI), thrombomodulin (TM), soluble suppression of tumorigenesis-2 factor (ST2), angiopoietin-2 (Ang-2)), innate immunity activation (neutrophil extracellular traps (NETs), soluble C5b-9 (sC5b-9)) and hemostasis/fibrinolysis (von Willebrand Factor antigen (VWF:Ag), ADAMTS-13 (A13), α2-antiplasmin (α2-AP), plasminogen activator inhibitor-1 antigen (PAI-1 Ag)) were measured and compared with those in cohorts of patients with sepsis and healthy donors.
RESULTS
Patients who developed CAR-T cell toxicities presented increased levels of sVCAM-1, sTNFRI and ST2 at the clinical onset versus postinfusion values. Twenty-four hours after infusion, ST2 levels were good predictors of any CAR-T cell toxicity, and combination of ST2, Ang-2 and NETs differentiated patients requiring intensive care unit admission from those with milder clinical presentations. Association of Ang-2, NETs, sC5b-9, VWF:Ag and PAI-1 Ag showed excellent discrimination between severe CAR-T cell toxicities and sepsis.
CONCLUSIONS
This study provides relevant contributions to the current knowledge of the CAR-T cell toxicities pathophysiology. Markers of endotheliopathy, innate immunity activation and hemostatic imbalance appear as potential laboratory tools for their prediction, severity and differential diagnosis.
Identifiants
pubmed: 37045474
pii: jitc-2022-006365
doi: 10.1136/jitc-2022-006365
pmc: PMC10106034
pii:
doi:
Substances chimiques
cell-associated neurotoxicity
0
Hemostatics
0
von Willebrand Factor
0
Plasminogen Activator Inhibitor 1
0
Interleukin-1 Receptor-Like 1 Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MD-R and EC have been granted by and received honoraria from Jazz Pharmaceuticals. SF and PC have collaborated with Jansen, Gilead, Kite, MSD, Alexion and Pfizer, outside of the submitted work. MP received speaker’s fee from Jazz Pharmaceuticals. The rest of authors have no competing interests to declare.
Références
Blood Adv. 2018 Jun 26;2(12):1495-1509
pubmed: 29945939
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Vascul Pharmacol. 2007 Jan;46(1):1-9
pubmed: 16920035
Bone Marrow Transplant. 2010 Sep;45(9):1417-22
pubmed: 20062097
Front Oncol. 2020 Jun 24;10:885
pubmed: 32670871
Mol Ther. 2021 Feb 3;29(2):636-644
pubmed: 33010231
Semin Thromb Hemost. 2022 Nov;48(8):978-987
pubmed: 36100234
Mol Ther Methods Clin Dev. 2018 Dec 06;12:134-144
pubmed: 30623002
Biol Blood Marrow Transplant. 2009 May;15(5):537-46
pubmed: 19361745
Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):23-32
pubmed: 18162218
Cancer Discov. 2017 Dec;7(12):1404-1419
pubmed: 29025771
Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):729-36
pubmed: 12615672
Clin Hematol Int. 2019 Mar 18;1(1):45-51
pubmed: 34595410
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
Blood Rev. 2019 Mar;34:45-55
pubmed: 30528964
Gut. 2016 Aug;65(8):1391-2
pubmed: 26984854
Clin Chim Acta. 2019 Aug;495:606-610
pubmed: 31181192
Nat Med. 2018 Jun;24(6):731-738
pubmed: 29808005
Front Immunol. 2020 Mar 20;11:482
pubmed: 32528460
Bone Marrow Transplant. 2011 Dec;46(12):1495-502
pubmed: 21460864
Front Immunol. 2019 Oct 09;10:2339
pubmed: 31649666
Shock. 2009 Apr;31(4):335-41
pubmed: 18791498
Bone Marrow Transplant. 2021 Dec;56(12):2889-2896
pubmed: 34584241
J Thromb Haemost. 2021 Aug;19(8):1948-1958
pubmed: 33872468
Nat Med. 2000 Apr;6(4):460-3
pubmed: 10742156
Int J Mol Sci. 2020 May 29;21(11):
pubmed: 32485958
Lancet Haematol. 2021 May;8(5):e355-e364
pubmed: 33894170
Front Immunol. 2022 Apr 08;13:877477
pubmed: 35464403
Blood. 2017 Nov 23;130(21):2295-2306
pubmed: 28924019
J Clin Oncol. 2020 Feb 10;38(5):415-422
pubmed: 31815579
Ann Hematol. 2019 Jul;98(7):1721-1732
pubmed: 31055613
Crit Care. 2019 Aug 15;23(1):280
pubmed: 31416465
Front Immunol. 2020 Dec 16;11:577027
pubmed: 33391257
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Bone Marrow Transplant. 2022 May;57(5):721-728
pubmed: 35184147
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5553-8
pubmed: 15060280
Shock. 2022 Jan 1;57(1):95-105
pubmed: 34172614
J Clin Pathol. 1993 May;46(5):470-3
pubmed: 8320330
Int J Hematol Oncol. 2017 Nov;6(3):75-93
pubmed: 30302228
Circ Res. 2000 Sep 29;87(7):603-7
pubmed: 11009566
Blood. 2015 Mar 26;125(13):2019-28
pubmed: 25712991
Basic Res Cardiol. 2008 Sep;103(5):398-406
pubmed: 18600364
Cancer Discov. 2017 Dec;7(12):1371-1373
pubmed: 29208775
Bone Marrow Transplant. 2021 Mar;56(3):570-580
pubmed: 32943758